Truist Financial Corp Purchases 4,525 Shares of Natera, Inc. $NTRA

Truist Financial Corp increased its position in Natera, Inc. (NASDAQ:NTRA) by 14.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,248 shares of the medical research company’s stock after buying an additional 4,525 shares during the quarter. Truist Financial Corp’s holdings in Natera were worth $6,124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Bank of Jackson Hole Trust bought a new stake in shares of Natera in the 1st quarter worth approximately $29,000. Oliver Lagore Vanvalin Investment Group bought a new stake in Natera in the second quarter worth $36,000. Rakuten Securities Inc. lifted its stake in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock worth $31,000 after purchasing an additional 119 shares during the last quarter. TCTC Holdings LLC lifted its stake in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after purchasing an additional 124 shares during the last quarter. Finally, ORG Partners LLC bought a new stake in Natera in the first quarter worth $32,000. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares in the company, valued at approximately $1,004,444.85. This represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $132.89, for a total value of $398,670.00. Following the completion of the transaction, the insider owned 123,059 shares of the company’s stock, valued at approximately $16,353,310.51. This trade represents a 2.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,464 shares of company stock worth $10,963,125 in the last ninety days. 5.63% of the stock is owned by company insiders.

Analyst Ratings Changes

NTRA has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Saturday, September 27th. Cowen reissued a “buy” rating on shares of Natera in a research note on Friday, August 8th. Piper Sandler reiterated an “overweight” rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Barclays reiterated an “overweight” rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Finally, Wells Fargo & Company began coverage on shares of Natera in a report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $192.88.

Natera Price Performance

NTRA stock opened at $170.38 on Tuesday. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $183.00. The company has a market cap of $23.38 billion, a P/E ratio of -89.20 and a beta of 1.74. The firm has a 50-day moving average of $161.82 and a 200 day moving average of $156.80.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same period in the previous year, the company earned ($0.30) earnings per share. Natera’s quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.